Search Icon
SideMenu
Home
Blog

Biosimilars Council Press Releases

Blog
  • Blog

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending
  • Blog

AAM All Access Podcast: CMMB’s Urgent Mission
  • Blog

Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
  • Blog

The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
  • Blog

Medicare Negotiations Serve as a Catalyst to a Perpetual Monopolyc
  • Blog

Despite Enrollment In Medicare Prescription Drug Coverage, Over Half of All Seniors Pay Full Cost for Many Generic Drugs
  • Blog

AAM All Access Podcast: Drug Shortages and the U.S. Supply Chain
  • Blog

Everything You Need to Know About Biosimilars – All in One Place
  • Blog

AAM Calls for Federal Trade Commission to Investigate PBM Business Practices
  • Blog

Generics Drive Savings Yet Patients Continue to Pay More
  • Blog

As Health Care Spending in US Projected to Increase, Generics and Biosimilars Expected to Moderate Growth
  • Blog

Challenges & Solutions for Prescription Drug Savings Identified by MedPAC
Load More